Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice

Endocrine Practice

Volumn 7, Issue 3, 2001, Pages 162-169

  Gegick, C G ^a   Altheimer, M D ^a  

^a Greensboro Endocrinol and Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES CONTROL; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING;

EID: 0034986314     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.7.3.162     Document Type: Article

References (17)

1. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2000 update
2. Clinical practice recommendations 2001
3. Troglitazone-induced hepatic failure leading to liver transplantation: A case report
4. Severe hepatotoxicity associated with troglitazone
5. An autopsy case of troglitazone-induced fulminant hepatitis
6. Benefits of computerized outcome analysis in diabetes management
7. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
8. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
9. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels
10. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: Results from the 11-year follow-up of the Paris Prospective Study
11. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
12. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
13. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
14. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38